> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Core EPS Rises 17% To $2.79 As Cancer Drugs Absorb Farxiga Generic Hit
- URL: https://www.bullished.co/astrazeneca-core-eps-rises-17-to-2-79-as-cancer-drugs-absorb-farxiga-generic-hit-8fd6aa21/
- Published: 2026-10-30T11:46:04.000Z
- Updated: 2026-10-30T11:46:04.000Z
- Description: Oncology revenue climbed 17% to $7,765 million in the third quarter, and the drugmaker kept its 2026 outlook unchanged.
- Author: Matteo Parrino
- Tags: Earnings, AZN, Industry: Healthcare

[AstraZeneca](https://www.bullished.co/tag/azn/), the drugmaker behind the cancer medicines Imfinzi, Tagrisso and Enhertu, said Friday that [third-quarter revenue rose 7% to $16,209 million](https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm?ref=bullished.co), with cancer growth outweighing the loss of exclusivity on Farxiga and Brilinta. Core earnings per share rose 17% to $2.79, and the company reconfirmed its 2026 guidance.

## Cancer drugs carry the quarter

Revenue grew 7% both as reported and at constant exchange rates. Core EPS rose 17% as reported and 19% at constant rates, while [reported EPS climbed 23%](https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm?ref=bullished.co) to $2.02, or 26% at constant rates.

Oncology product revenue rose 17% to $7,765 million. Imfinzi grew 24% to $1,990 million as reported, Tagrisso 12% to $2,087 million, and Enhertu 36% to $969 million.

The drag came from cardiovascular and metabolic drugs. Farxiga fell 25% to $1,605 million and Brilinta fell 48% to $75 million. Tezspire, the asthma drug, rose 50% to $429 million, and rare disease revenue reached $2,633 million.

Core operating profit rose 17% as reported to $5,855 million, or 20% at constant rates.

## Guidance holds for 2026

At constant exchange rates, AstraZeneca still expects full-year total revenue to grow by a mid-to-high single-digit percentage and core EPS by a low double-digit percentage. It expects a core tax rate of 18-22%.

CEO Pascal Soriot said the company has had approvals for four new medicines and 12 positive late-stage trial readouts, with "a collective peak year revenue potential well in excess of ten billion dollars." The company counts 47 approvals in major regions since its fourth-quarter 2025 results.

## Deals, restructuring and debt

In October AstraZeneca completed a $2 billion equity investment in Summit Therapeutics, giving it rights equal to about 12.0% of Summit's outstanding common stock. It also launched a restructuring programme, Reshaping for Sustainable Growth, expected to cost up to $2.0 billion in one-time charges and deliver $1.5 billion in annualised pre-tax run-rate benefits, with activities essentially complete by the end of 2029.

Net debt rose by $2,459 million over nine months to $25,833 million. The company intends to raise its 2026 dividend to $3.30 per share.

AstraZeneca plans to publish full-year and fourth-quarter 2026 results on 9 February 2027.

### Sources

- [Form 6-K — 3RD QUARTER RESULTS](https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm?ref=bullished.co) — SEC EDGAR
- [AstraZeneca PLC Non-GAAP EPS of $2.79, revenue of $16.21B beats by $210M; reaffirms FY2026 | Seeking Alpha](https://seekingalpha.com/news/4661211-astrazeneca-plc-non-gaap-eps-of-279-revenue-of-1621b-beats-by-210m-reaffirms-fy2026-outlook?ref=bullished.co) — seekingalpha.com
- [AstraZeneca Q3 profit beats estimates as cancer drug sales drive growth (AZN:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4661203-astrazeneca-q3-profit-beats-estimates-as-cancer-drug-sales-drive-growth?ref=bullished.co) — seekingalpha.com
- [《業績》阿斯利康(AZN.US)上季收入增長7% 盈利勝預期](https://hk.finance.yahoo.com/news/%E6%A5%AD%E7%B8%BE-%E9%98%BF%E6%96%AF%E5%88%A9%E5%BA%B7-azn-us-%E4%B8%8A%E5%AD%A3%E6%94%B6%E5%85%A5%E5%A2%9E%E9%95%B77-083130713.html?ref=bullished.co) — Yahoo Finance

### More on AstraZeneca

- [Enhertu Wins EU Approval After Surgery, Cutting Recurrence Risk 53% — AstraZeneca Owes Daiichi $75 Million](https://www.bullished.co/enhertu-wins-eu-approval-after-surgery-cutting-recurrence-risk-53-astrazeneca-owes-daiichi-6f920367/)
- [Ultomiris Gets US Accelerated Approval In IgA Nephropathy On A 43.4% Proteinuria Reduction](https://www.bullished.co/ultomiris-gets-us-accelerated-approval-in-iga-nephropathy-on-a-43-4-proteinuria-reduction-3d95ea4b/)

[All AstraZeneca (AZN) coverage →](https://www.bullished.co/tag/azn/)